Current approaches to the prevention and treatment of postmenopausal osteoporosis

American Journal of Health-System Pharmacy

Volumn 60, Issue 9, 2003, Pages 883-901

  Follin, Sheryl L ^a   Hansen, Laura B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bisphosphonates; Calcitonin; Calcium; Calcium regulators; Estrogens; Hormones; Minerals; Osteoporosis; Parathyroid; Parathyroid hormones; Postmenopause; Vitamin D; Vitamins

Indexed keywords

'POSTURE'; ALENDRONIC ACID; ALKA MINTS; ALKALINE PHOSPHATASE BONE ISOENZYME; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CITRATE CALCIUM; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; ESTROGEN; ETIDRONIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRIFLAVONE; ISOFLAVONE; OSTEOCALCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHYTOESTROGEN; PROCOLLAGEN; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; THIAZIDE DIURETIC AGENT; TUMS; VIACTIVE; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; BARRETT ESOPHAGUS; BONE DENSITY; BONE MASS; BONE STRENGTH; BONE TURNOVER; CALCIUM INTAKE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; EPISTAXIS; ESOPHAGITIS; EXERCISE; FALLING; FRACTURE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; LABORATORY TEST; LEG CRAMP; LIFESTYLE; NASAL PRURITUS; NOSE IRRITATION; OSTEOLYSIS; OSTEOPENIA; PHYSICAL EXAMINATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SMOKING CESSATION; THROMBOEMBOLISM; UNITED STATES; VITAMIN INTAKE;

EID: 0037632771     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.9.883     Document Type: Review

References (206)

1. National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass. 2002. www.nof.org/advocacy/prevalence/index.htm (accessed 2002 Jun 21).
2. Hodgson SF, Watts NB. American Association of Clinical Endocrinologists: 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001; 7:293-312.
3. Siris ES, Miller PD, Barrett-Connor E et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA. 2001; 286:2815-22.
4. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. www.nof.org (accessed 2002 Jun 21).
5. Riggs BL, Melton LJ. The world wide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995; 17: 5055-5155.
6. Melton LJ, Chrishilles EA, Cooper C et al. How many women have osteoporosis? J Bone Miner Res. 1992; 7:1005-10.
7. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359:1761-7.
8. Cauley JA, Thompson DE, Ensrud KC et al. Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11:556-61.
9. Zuckerman JD. Hip fracture. N Engl J Med. 1996; 334:1519-25.
10. Center JR, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353:878-82.
11. Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women. Arch Intern Med. 1999; 159: 1215-20.
12. Cooper C, Atkinson EJ, O'Fallon WM et al. Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992; 7:221-7.
13. Woolf AD, Dixon AS. Osteoporosis: a clinical guide. 2nd ed. London: Livery House; 1998.
14. Tosteston AN, Gabriel SE, Grove MR et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int. 2001; 12:1042-9.
15. Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993; 137:1001-5.
16. Greendale GA, Barrett-Conner E, Ingles S et al. Late physical and functional effects of osteoporotic fracture in women: the Rancho Bernardo Study. J Am Geriatr Soc. 1995; 43:955-61.
17. Adachi JD, Loannidis D, Berger C et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2001; 12:903-8.
18. Trombetti A, Herrmann F, Hoffmeyer P et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int. 2002; 13:731-7.
19. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am. 2001; 27:255-62.
20. National Osteoporosis Foundation. Disease statistics-fast facts. www.nof.org/osteoporosis/stats.htm (accessed 2002 Jun 21).
21. National Institutes of Health Osteoporosis and Related Bone DiseasesNational Resource Center. Fast facts on osteoporosis. 2002. www.osteo.org/newfile.asp?doc=fast&doctitle=Fast+Facts+on+ Osteoporosis&doctype=HTML+Fact+Sheet (accessed 2002 Jun 21).
22. Whitfield JF. The parathyroid hormones (PTHS): anabolic tools for mending fractures and treating osteoporosis. www.medscape.com/viewprogram/604_pnt (accessed 2002 Jun 27).
23. Lee CA, Einhorn TA. The bone organ system. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. 2nd ed. San Diego, CA: Academic Press; 2001:3-19
24. Heaney RP. Pathophysiology of osteoporosis. Endocrinol Metab Clin North Am. 1998; 27:255-65.
25. Miller PD, Zapalowski C, Kulak CA et al. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab. 1999; 84: 1867-71.
26. Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab. 2002; 87:2460-6.
27. Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res. 1995; 10:1534-6.
28. Compston JE. Sex steroids and bone. Physiol Rev. 2001; 81:419-47.
29. Delmas PD, Eastell R, Garnero P et al. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000; 11(suppl 6):S2-17.
30. Ross PD. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am. 1998; 27:289-95.
31. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988; 319:1701-7.
32. Nevitt MC, Cummings SR. Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. J Am Geriatr Soc. 1993; 41:1226-34.
33. Greenspan SL, Meyers ER, Maitland LA et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. 1994; 271:128-33.
34. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002; 77: 453-68.
35. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002; 9:84-101.
36. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int. 2000; 11:637-59.
37. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. N Engl J Med. 1995; 332: 767-73.
38. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Treatment. Osteoporosis, prevention and treatment. JAMA. 2001; 285:785-95.
39. Kanis JA. Diagnosis of osteoporosis and assessment of fracture. Lancet. 2002; 359:1929-36.
40. Melton LJ, Atkinson EJ, Cooper C et al. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999; 10:214-21.
41. Klotzbuecher CM, Ross PD, Landsman PB et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15:721-39.
42. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2000; 285: 320-3.
43. Cummings SR, Black DM, Nevitt MC et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993; 341:72-5.
44. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrences of osteoporotic fractures. BMJ. 1996; 312: 1254-9.
45. Miller PD, Bonnick SL, Johnston CC et al. The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? J Clin Densitom. 1998; 1:211-7.
46. Kanis JA, Gluer CC. International Osteoporosis Foundation: an update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int. 2000; 11:192-202.
47. Melton LJ, Atkinson EJ, O'Fallon WM et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993; 8:1227-33.
48. Faulkner KG. Bone densitometry: choosing the right skeletal site to measure. J Clin Densitometry. 1998; 1:279-85.
49. Cadarette SM, Jaglal SB, Murray TM et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA. 2001; 286:57-63.
50. Black DM, Steinbuch M, Palermo L et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int. 2001; 12:519-28.
51. Miller PD. Management of osteoporosis. Adv Intern Med. 1999; 44:175-207.
52. Khosla S, Kleerekoper M. Biochemical markers of bone turnover. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1999:128-33.
53. Ernst E. Exercise for female osteoporosis. Sports Med. 1998; 25:359-68.
54. Gregg EW, Pereira MA, Caspersen CJ. Physical activity, falls and fractures among older adults: a review of the epidemiologic evidence. J Am Geriatr Soc. 2000; 48:883-93.
55. Rutherford OM. Is there a role for exercise in the prevention of osteoporotic fractures? Br J Sports Med. 1999; 33:378-86.
56. Dalsky GP, Stocke KS, Ehsani AA et al. Weight-bearing exercise training and lumbar bone mineral content in postmenopausal women. Ann Intern Med. 1998; 108:824-8.
57. Nelson ME, Fiatarone MA, Morganti CM et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA. 1994; 272:1909-14.
58. Henderson NK, White CP, Eisman JA. The roles of exercise and fall risk reduction in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998; 27:369-87.
59. Marcus R. Role of exercise in preventing and treating osteoporosis. Rheum Dis Clin North Am. 2001; 27:131-41.
60. Menkes A, Mazel S, Redmond RA et al. Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men. J Appl Physiol. 1993; 74:2478-84.
61. Gold DT, Lee LS, Tresolini CP, eds. Working with patients to prevent, treat and manage osteoporosis: a curriculum guide for the health professions. 3rd ed. Durham, NC: Center for the Study of Aging and Human Development, Duke University; 2001.
62. Hollenbach KA, Barrett-Connor E, Edelstein SL et al. Cigarette smoking and bone mineral density in older men and women. Am J Public Health. 1993; 83: 1265-70.
63. Bjarnason NH, Christiansen C. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 2000; 85:590-6.
64. Rapuri PB, Gallagher JC, Balhorn KE et al. Smoking and bone metabolism in elderly women. Bone. 2000; 27:429-36.
65. Cornuz J, Feskanich D, Willett WC et al. Smoking, smoking cessation, and risk of hip fracture in women. Am J Med. 1999; 106:311-4.
66. Hoidrup S, Prescott E, Sorensen TI et al. Tobacco smoking and risk of hip fracture in men and women. Int J Epidemiol. 2000; 29:253-9.
67. Bauer DC, Frowner WS, Cauley JA et al. Factors associated with appendicular bone mass in older women. Ann Intern Med. 1993; 118:657-65.
68. Huopio J, Kroger H, Honkanen R et al. Risk factors for perimenopausal fractures: a prospective study. Osteoporos Int. 2000; 11:219-27.
69. Heaney RP, Rafferty K. Carbonated beverages and urinary calcium excretion. Am J Clin Nutr. 2001; 74:343-7.
70. Rapuri PB, Gallagher JC, Kinayamu HK et al. Caffeine intake increases the rate of bone loss in elderly women and interacts with vitamin D receptor genotypes. Am J Clin Nutr. 2001; 74:694-700.
71. Hansen SA, Folsom AR, Kushi LH et al. Association of fractures with caffeine and alcohol in postmenopausal women: the Iowa Women's Health Study. Public Health Nutr. 2000; 3:253-61.
72. Rubenstein LZ, Robbins AS, Josephson KR et al. The value of assessing falls in an elderly population: a randomized clinical trial. Ann Intern Med. 1990; 113:308-16.
73. Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging. 1998; 12:43-53.
74. Kannus P, Parkkari J, Niemi S et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000; 343:1506-13.
75. Kanis JA. The use of calcium in the management of osteoporosis. Bone. 1999; 24: 279-90.
76. Heaney RP, Dawson-Hughes B, Gallagher JC et al. The role of calcium in peri- and postmenopausal women: consensus opinion of the North American Menopause Society. Menopause. 2001; 8: 84-95.
77. Akesson K, Lau KW, Bayling DJ. Rationale for active vitamin D analog therapy in senile osteoporosis. Calcif Tissue Int. 1997; 60:100-5.
78. Reid IR, Ames RW, Evans MC et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med. 1995; 98:331-5.
79. Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res. 1997; 12:1321-9.
80. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337:670-6.
81. Reid IR. The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998; 27: 389-98.
82. Specker BL. Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density. J Bone Miner Res. 1996; 11:1539-44.
83. Dawson-Hughes B, Dallal GE, Krall EA et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med. 1990; 323:878-83.
84. Recker RR, Davies KM, Doud RM et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. Ann Intern Med. 1999; 130:897-904.
85. Aloia JF, Vaswani A, Yeh JK et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med. 1994; 120:97-103.
86. Lips P, Graafmans WC, Ooms ME et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med. 1996; 124:400-6.
87. NIH Consensus Development Panel on Optimal Calcium Intake. Optimal calcium intake. JAMA. 1994; 272:1942-8.
88. Alaimo K, McDowell MA, Briefel RR et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, phase 1, 1988-1991. Adv Data. 1994; 258:1-28.
89. Heller HJ, Stewart A, Haynes S et al. Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol. 1999; 39: 1151-4.
90. Standing Committee on the Scientific Evaluation of Dietary Reference Intake, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press; 1997.
91. Heaney RP, Dowell MS, Barger-Lux MJ. Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int. 1999; 9:19-23.
92. Miller DR, Hanel HJ. Prevention and treatment of osteoporosis. US Pharm. 1999; Jun:81-92.
93. Rodan GA, Raisz LG, Bilezikian JP. Pathophysiology of osteoporosis. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. San Diego, CA: Academic Press; 2002:1275-89.
94. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA. 2002; 287:3116-26.
95. Zittermann A. Effects of vitamin K on calcium and bone metabolism. Curr Opin Clin Nutr Metab Care. 2001; 4: 483-7.
96. Feskanich D, Weber P, Willett WC et al. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999; 69:74-9.
97. Murray L, ed. Drug Topics red book. Montvale, NJ: Thomson Medical Economics; 2002.
98. Proctor & Gamble Pharmaceuticals. Personal communication. 2002 Oct.
99. Dunn CJ, Goa KL. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001; 61:605-712.
100. Sharpe M, Noble S, Spencer CM. Alendronate: an update of its use in osteoporosis. Drugs. 2001; 61:999-1039.
101. Food and Drug Administration. Alendronate sodium tablets, 35 & 70 mg, Rx-tentatively approved. www.fda.gov/cder/approval/index.htm (accessed 2002 Jun 24).
102. Actonel (risedronate sodium) package insert. Cincinnati, OH: Proctor & Gamble Pharmaceuticals; 2002 May.
103. Fosamax (alendronate sodium) package insert. Whitehouse Station, NJ: Merck & Co.; 2001 Jan.
104. Taggart H, Bolognese MA, Lindsay R et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc. 2002; 77:262-70.
105. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999; 282:1344-52.
106. McClung M, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001; 344:333-40.
107. De Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996; 335: 1016-21.
108. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med. 1998; 338:485-92.
109. McClung M, Clemmensen B, Daifotis A et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann Intern Med. 1998; 128:253-61.
110. Liberman UA, Weiss SR, Broll J et al. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-43.
111. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA. 1998; 280:2077-82.
112. Tonino RP, Meunier PJ, Emkey R et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000; 85:3109-15.
113. Mortensen L, Charles R, Bekker PJ et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998; 83: 396-402.
114. Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000; 11: 83-91.
115. Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:1535-41.
116. Black DM, Thompson DE, Bauer DC et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab. 2000; 85:4118-24.
117. Watts NB, Brown J, Hosking D et al. Sustained fracture risk reduction over 5 years with risedronate therapy. Paper presented at American Society of Bone and Mineral Research 23rd Annual Meeting. Phoenix, AZ; 2001 Oct 12.
118. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res. 2000; 12:1-12.
119. Greenspan S, Rizzoli R, Roux C et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. Paper presented at Endocrine Society 83rd Annual Meeting. Denver, CO; 2001 Jun 20.
120. Lindsay R, Adachi JD, Emkey RD et al. Once-a-week (35 mg) risedronate is as effective as daily (5 mg). Osteoporos Int. 2002; 13(suppl 1):S16. Abstract.
121. Watta NB, Li Z, Hoseyni MS et al. Efficacy of once-a-week risedronate in reducing vertebral fracture risk. Osteoporos Int. 2002; 13(suppl 1):S17-8. Abstract.
122. Johnston CC, Bjarnason NH, Cohen FJ et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med. 2000; 160:3044-50.
123. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282:637-45.
124. Maricic M, Adachi JD, Sarkar S et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002; 162:1140-3.
125. Walsh B, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998; 279: 1445-51.
126. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997; 337:1641-7.
127. Barrett-Connor E, Grady D, Sashegyi A et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002; 287:847-57.
128. Yaffe K, Krueger K, Sarkar S et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med. 2001; 344:1207-13.
129. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann N Y Acad Sci. 2000; 949:181-5.
130. Cummings SR, Eckert S, Krueger K et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA. 1999; 281:2189-97.
131. Evista (raloxifene hydrochloride) package insert. Indianapolis, IN: Eli Lilly; 2001 Mar.
132. Miacalcin (calcitonin) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 1998 Dec.
133. Overgaard K, Hansen MA, Jensen AB et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992; 305:556-61.
134. Thamsborg G, Jensen JE, Kollerup G et al. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone. 1996; 18:207-12.
135. Chestnut CH, Silverman S, Andriano K et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000; 109: 267-76.
136. Lyritis GP, Tsakalakos N, Magiasis B et al. Analgesic effect of salmon-calcitonin in osteoporotic vertebral fractures: a double blind, placebo-controlled clinical study. Calcif Tissue Int. 1991; 49:369-72.
137. Rifat SF, Kiningham RB, Peggs JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract. 1992; 35:93-6.
138. Pun KK, Chan LW. Analgesic effect of salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989; 11:205-9.
139. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 1996; 276:1389-96.
140. Villareal DT, Binder EF, Williams DB et al. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001; 286:815-20.
141. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA. 1997; 277:543-7.
142. Felson DT, Zhang Y, Hannan MT et al. The effects of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993; 329:1141-6.
143. Prestwood KM, Kenny AM, Unson C et al. The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab. 2000; 85:4462-9.
144. Lindsay R, Gallagher JC, Kleerekoper M et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002; 287:2668-76.
145. Gass M, Liu J, Rebar RW. The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density. Maturitas. 2001; 41:143-7.
146. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992; 117:1-9.
147. Cauley JA, Seeley DG, Ensrud K et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995; 122:9-16.
148. Grady D, Rubin SM, Petitti DM et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117:1016-37.
149. Reginster JY, Bruyere O, Audran M et al. Do estrogens effectively prevent osteoporosis-related fractures? Calcif Tissue Int. 2000; 67:191-4.
150. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001; 285: 2891-7.
151. Nelson HD, Humphrey LL, Nyugren P et al. Postmenopausal hormone replacement therapy. JAMA. 2002; 288:872-81.
152. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.
153. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996; 335: 453-61.
154. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women (HERS trial). JAMA. 1998; 280:605-13.
155. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000; 343:522-9.
156. Alexander KP, Newby LK, Hellcamp AS et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol. 2001; 38:1-7.
157. Grodstein F, Manson JE, Stampfer MJ et al. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study. Ann Intern Med. 2001; 135:1-8.
158. Heckbert SR, Kaplan RC, Weiss NS et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med. 2001; 162:1709-13.
159. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288: 49-57.
160. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332:1589-93.
161. Chen CL, Weiss NS, Newcomb P et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002; 287: 734-41.
162. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997; 350: 1047-59.
163. Hulley S, Furberg C, Barrett-Connor E et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA. 2002; 288:58-66.
164. Grady D, Wenger NK, Herrington DM et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med. 2000; 132: 689-96.
165. Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventative Services Task Force. Ann Intern Med. 2002; 136:680-90.
166. Grodstein F, Martinez EM, Platz EA et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998; 128:705-12.
167. Women's Health Initiative. Hormone Replacement Therapy Study fact sheet. www.nhlbi.nih.gov/whi/hrt.htm (accessed 2002 Oct 7).
168. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med. 1999; 131: 605-16.
169. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Climacteric. 2001; 4:58-74.
170. Johnell O, Scheele WH, Lu Y et al. Effects of raloxifene and alendronate on mineral density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87:985-92.
171. Lindsay R, Cosman F, Lobo RA et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999; 84:3076-81.
172. Bone HG, Greenspan SL, McKeever C et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000; 85:720-6.
173. Harris ST, Eriksen E, Davidson M et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2001; 86:1890-7.
174. Rubin MR, Cosman F, Linday R et al. The anabolic effects of parathyroid hormone. Osteoporos Int. 2002; 13:267-77.
175. Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab. 2001; 12:281-3.
176. Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16:1846-53.
177. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-41.
178. NDA 21-318: LY333334 (teriparatide) for osteoporosis. Medical safety review. www.fda.gov/ohrms/dockets/ac/01/briefing/3761b2_03_Medical%20Review%20 Safety.htm (accessed 2002 Jun 27).
179. Executive summary for advisory committee. www.fda.gov/ohrms/dockets/ac/01/briefing/3761b2_02_Medical%20Review%20 Efficacy.pdf (accessed 2002 Jun 27).
180. Watts NB, Harris ST, Genant HK et al. Intermittant cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990; 323:73-9.
181. Miller PD, Watts NB, Licata AA et al. Cyclic etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med. 1997; 103:468-76.
182. Thiebaud S, Burckhardt P, Melchoir J et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int. 1994; 42:76-83.
183. Peretz A, Body JJ, Dumon JC et al. Cyclic pamidronate infusions in postmenopausal osteoporosis. Maturitas. 1996; 25: 69-75.
184. Reid IR, Brown JP, Burckhardt P et al. Intravenous zolendronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002; 346: 653-61.
185. LaCroix AZ, Wienpahl J, White LR et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med. 1990; 322:286-90.
186. Felson DT, Sloutskis D, Anderson JJ et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA. 1991; 265:370-3.
187. Cauley JA, Cummings SR, Seeley DG et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. Ann Intern Med. 1993; 118:666-73.
188. LaCroix AZ, Ott SM, Ichikawa L et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 2000; 133:516-26.
189. Reid IR, Ames RW, Orr-Walker BJ et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000; 109:362-70.
190. Mundy G, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286: 1946-9.
191. Pasco JA, Kotowicz MA, Henry MJ et al. Statin use, bone mineral density, and fracture risk. Geelong Osteoporosis Study. Arch Intern Med. 2002; 162:537-40.
192. Meier CR, Schlienger RG, Kraenzlin ME et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000; 283:3205-10.
193. Wang PS, Solomon DH, Mogun H et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000; 283:3211-6.
194. Reid IR, Hague W, Emberson J et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet. 2001; 357:509-12.
195. LaCroix AZ, Cauley JA, Jackson R et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS). J Bone Miner Res. 2000; 15(suppl 1):S155.
196. Natural Pharmacist. Principal proposed treatments for osteoporosis. www.tnp.com/encyclopedia/condition/190/83 (accessed 2001 Aug).
197. Fanti P, Monier-Faugere MC, Geng Z et al. The phytoestrogen genistein reduced bone loss in short-term ovariectomized rats. Osteoporos Int. 1998; 8:274-81.
198. Potter SM, Baum JA, Teng H et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr. 1998; 68:1375S-9S.
199. Alekel DL, St. Germain A, Peterson CT et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000; 72:844-52.
200. Gallagher JC, Rafferty K, Haynatzka V et al. The effect of soy protein on bone metabolism. J Nutr. 2000; 130:666S-9S. Abstract.
201. Adami S, Bufalino L, Cervetti R et al. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int. 1997; 7:119-25.
202. Agnusdei D, Crepaldi G, Isaia G et al. A double blind placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int. 1997; 61:142-7.
203. Gennari C, Adami S, Agnusdei D et al. Effect of chronic treatment with
204. Agnusdei D, Bufalino L. Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int. 1997; 61:S23-7.
205. Forteo package insert. Indianapolis, IN: Eli Lilly and Company; 2002.
206. Marcus R, Wang O, Satterwhite J et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003; 18:18-23.